



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 28755

Title: Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies

Reviewer's code: 03438798

Reviewer's country: Italy

Science editor: Yuan Qi

Date sent for review: 2016-07-16 20:00

Date reviewed: 2016-08-09 18:01

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this letter, authors faced the problem of the lack of preclinical models of cholangiocarcinoma. It is a huge question, which gave limited options to study new therapies. During the years, with a great amount of work, authors established and characterized an important number of xenografts and cell lines, providing new suitable models to study this aggressive malignancy. As concern reference 3, "Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma", authors performed all the experiments using four cell lines not established from their group. Please, explain why they include this paper as reference in the letter to the editor. The molecular characteristics of this kind of tumor are strictly dependent from ethnicity (mutations, risk factors). These models could pave the way to new molecular studies and to the identification of new therapies mainly for Eastern Countries patients.